Citadel Advisors’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.1M | Buy |
1,589,035
+271,577
| +21% | +$3.09M | ﹤0.01% | 1022 |
|
|
2025
Q1 | $15.7M | Buy |
1,317,458
+465,939
| +55% | +$5.54M | ﹤0.01% | 1015 |
|
|
2024
Q4 | $16M | Sell |
851,519
-679,686
| -44% | -$12.8M | ﹤0.01% | 1051 |
|
|
2024
Q3 | $34.4M | Buy |
1,531,205
+490,539
| +47% | +$11M | 0.01% | 624 |
|
|
2024
Q2 | $21.7M | Buy |
1,040,666
+825,950
| +385% | +$17.2M | ﹤0.01% | 831 |
|
|
2024
Q1 | $3.16M | Buy |
214,716
+182,847
| +574% | +$2.69M | ﹤0.01% | 2106 |
|
|
2023
Q4 | $329K | Sell |
31,869
-36,599
| -53% | -$378K | ﹤0.01% | 4158 |
|
|
2023
Q3 | $538K | Buy |
68,468
+53,002
| +343% | +$417K | ﹤0.01% | 3676 |
|
|
2023
Q2 | $155K | Sell |
15,466
-41,024
| -73% | -$410K | ﹤0.01% | 4562 |
|
|
2023
Q1 | $502K | Sell |
56,490
-62,717
| -53% | -$557K | ﹤0.01% | 3860 |
|
|
2022
Q4 | $1.31M | Sell |
119,207
-19,472
| -14% | -$214K | ﹤0.01% | 2968 |
|
|
2022
Q3 | $1.81M | Buy |
+138,679
| New | +$1.81M | ﹤0.01% | 2835 |
|
|
2022
Q2 | – | Sell |
-211,783
| Closed | -$2.97M | – | 6635 |
|
|
2022
Q1 | $2.97M | Buy |
211,783
+158,504
| +297% | +$2.22M | ﹤0.01% | 2576 |
|
|
2021
Q4 | $1.54M | Buy |
53,279
+7,973
| +18% | +$231K | ﹤0.01% | 3325 |
|
|
2021
Q3 | $1.36M | Sell |
45,306
-5,365
| -11% | -$161K | ﹤0.01% | 3444 |
|
|
2021
Q2 | $1.34M | Buy |
+50,671
| New | +$1.34M | ﹤0.01% | 3651 |
|
|
2021
Q1 | – | Sell |
-9,184
| Closed | -$302K | – | 6641 |
|
|
2020
Q4 | $302K | Sell |
9,184
-236,016
| -96% | -$7.76M | ﹤0.01% | 4229 |
|
|
2020
Q3 | $8.56M | Buy |
+245,200
| New | +$8.56M | ﹤0.01% | 1191 |
|